Sep 21, 2016 9:10 am EDT Cerecor Announces Completion of Enrollment in Phase 2 Clinical Trial with CERC-301 as an Oral, Adjunctive Treatment of Major Depressive Disorder
Sep 12, 2016 9:10 am EDT Cerecor Enters Into a $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
Sep 6, 2016 9:10 am EDT Cerecor Announces Last Patient Enrolled in Phase 2 Clinical Trial with CERC-501 for Smoking Cessation
Sep 1, 2016 9:10 am EDT Cerecor to Present at 23rd Annual NewsMakers in the Biotech Industry Conference in New York City, September 9, 2016
Aug 29, 2016 9:10 am EDT Cerecor Inc. Announces Initiation of Second CERC-501 Phase 2 Clinical Trial in Smokers
Aug 22, 2016 9:10 am EDT Cerecor to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
Jul 25, 2016 9:10 am EDT Cerecor Announces Research Grant from the Department of Defense to Study CERC-501 in Animal Models for Co-Morbid Post-Traumatic Stress Disorder and Alcohol Use Disorder
Jul 20, 2016 9:52 am EDT Cerecor Announces $1.0 Million Research & Development Grant from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health
